SCHEMBL5928818

SCHEMBL5928818

COc1ccc(N2N=C(C)C(C=O)C2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ ATM Q13315 1/20 0.50
▸ APP P05067 1/20 0.46
▸ MAPT P10636 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ACSS2 Q9NR19 3/20 0.43
▸ LOX P28300 1/20 0.42
▸ LOXL3 P58215 1/20 0.42
▸ LOXL4 Q96JB6 1/20 0.42
▸ LOXL2 Q9Y4K0 1/20 0.42
▸ CES2 O00748 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5928903 0.86 MAPT (0.48) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL22678453 0.85 MAPT (0.41) MEN1KMT2AATMMAPTALDH1A1
SCHEMBL22670353 0.83 ACSS2 (0.48) MEN1KMT2AATMMAPTALDH1A1
SCHEMBL5928736 0.82 MAPT (0.49) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL5713339 0.81 LOX (0.63) MEN1KMT2AATMMAPTALDH1A1
SCHEMBL22670153 0.80 HPGD (0.41) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL6265187 0.79 MEN1 (0.52) MEN1KMT2AATMAPPMAPT
SCHEMBL22670032 0.78 POLB (0.49) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL28702514 0.75 ACSS2 (0.55) MEN1KMT2AATMAPPMAPT
SCHEMBL22671090 0.73 ACSS2 (0.37) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020230136-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 — — WO disclosed
US-20060229324-A1 Quinazolin-4-one derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2006-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229324-A1 Quinazolin-4-one derivatives HPGDS, PTGS1, PTGDR MEN1 3991/4885KMT2A 2207/4885ATM 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback